Punxsutawney Area Hospital | |
81 Hillcrest Drive, Punxsutawney, Pennsylvania 15767 | |
(814) 938-1800 | |
Name | Punxsutawney Area Hospital |
---|---|
Type | Acute Care Hospital |
Location | 81 Hillcrest Drive, Punxsutawney, Pennsylvania |
Ownership | Voluntary non-profit - Private |
Emergency Services | Yes |
Medicare ID (CCN) | 390199 |
NPI Number | 1003972415 |
Organization Name | PUNXSUTAWNEY AREA HOSP EM MED FPA |
Address | 81 Hillcrest Dr, Punxsutawney, PA 15767 |
Hospital Type | General Acute Care Hospital |
Phone Number | 814-938-1810 |
News Archive
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
The controversy over recent breast cancer screening guidelines offers an opportunity to engage individual patients in an informed discussion of the importance of evidence-based clinical efficacy assessments in contributing to better care decisions, Donna Sweet, MD, MACP today told the Subcommittee on Health of the House Energy and Commerce Committee. Dr. Sweet testified at a hearing, Breast Cancer Screening Recommendations, on behalf of the American College of Physicians (ACP).
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has reached agreement with the U.S. Food and Drug Administration for two special protocol assessments for the Company's pivotal Phase 3 program with NAV5001 as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor.
Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and at Ghent University in Ghent, Belgium, have identified a new role for certain lung cells in the immune response to airborne allergens.
› Verified 8 days ago
NPI Number | 1083770499 |
Organization Name | PUNXSUTAWNEY HOSP CARD PHYS FPA |
Address | 81 Hillcrest Dr, Punxsutawney, PA 15767 |
Hospital Type | General Acute Care Hospital |
Phone Number | 814-938-1810 |
News Archive
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
The controversy over recent breast cancer screening guidelines offers an opportunity to engage individual patients in an informed discussion of the importance of evidence-based clinical efficacy assessments in contributing to better care decisions, Donna Sweet, MD, MACP today told the Subcommittee on Health of the House Energy and Commerce Committee. Dr. Sweet testified at a hearing, Breast Cancer Screening Recommendations, on behalf of the American College of Physicians (ACP).
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has reached agreement with the U.S. Food and Drug Administration for two special protocol assessments for the Company's pivotal Phase 3 program with NAV5001 as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor.
Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and at Ghent University in Ghent, Belgium, have identified a new role for certain lung cells in the immune response to airborne allergens.
› Verified 8 days ago
NPI Number | 1265449870 |
Organization Name | PUNXSUTAWNEY AREA HOSPITAL INC |
Address | 81 Hillcrest Dr, Punxsutawney, PA 15767 |
Hospital Type | General Acute Care Hospital |
Phone Number | 814-938-1800 |
News Archive
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
The controversy over recent breast cancer screening guidelines offers an opportunity to engage individual patients in an informed discussion of the importance of evidence-based clinical efficacy assessments in contributing to better care decisions, Donna Sweet, MD, MACP today told the Subcommittee on Health of the House Energy and Commerce Committee. Dr. Sweet testified at a hearing, Breast Cancer Screening Recommendations, on behalf of the American College of Physicians (ACP).
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has reached agreement with the U.S. Food and Drug Administration for two special protocol assessments for the Company's pivotal Phase 3 program with NAV5001 as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor.
Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and at Ghent University in Ghent, Belgium, have identified a new role for certain lung cells in the immune response to airborne allergens.
› Verified 8 days ago
NPI Number | 1336339928 |
Organization Name | PUNXSUTAWNEY AREA HOSPITAL INC |
Address | 81 Hillcrest Dr, Punxsutawney, PA 15767 |
Hospital Type | General Acute Care Hospital |
Phone Number | 814-938-1810 |
News Archive
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
The controversy over recent breast cancer screening guidelines offers an opportunity to engage individual patients in an informed discussion of the importance of evidence-based clinical efficacy assessments in contributing to better care decisions, Donna Sweet, MD, MACP today told the Subcommittee on Health of the House Energy and Commerce Committee. Dr. Sweet testified at a hearing, Breast Cancer Screening Recommendations, on behalf of the American College of Physicians (ACP).
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has reached agreement with the U.S. Food and Drug Administration for two special protocol assessments for the Company's pivotal Phase 3 program with NAV5001 as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor.
Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and at Ghent University in Ghent, Belgium, have identified a new role for certain lung cells in the immune response to airborne allergens.
› Verified 8 days ago
NPI Number | 1982048666 |
Organization Name | PUNXSUTAWNEY HOSPITAL HOSPITALIST |
Address | 81 Hillcrest Dr, Punxsutawney, PA 15767 |
Hospital Type | General Acute Care Hospital |
Phone Number | 814-938-1810 |
News Archive
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
The controversy over recent breast cancer screening guidelines offers an opportunity to engage individual patients in an informed discussion of the importance of evidence-based clinical efficacy assessments in contributing to better care decisions, Donna Sweet, MD, MACP today told the Subcommittee on Health of the House Energy and Commerce Committee. Dr. Sweet testified at a hearing, Breast Cancer Screening Recommendations, on behalf of the American College of Physicians (ACP).
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has reached agreement with the U.S. Food and Drug Administration for two special protocol assessments for the Company's pivotal Phase 3 program with NAV5001 as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor.
Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and at Ghent University in Ghent, Belgium, have identified a new role for certain lung cells in the immune response to airborne allergens.
› Verified 8 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.
The controversy over recent breast cancer screening guidelines offers an opportunity to engage individual patients in an informed discussion of the importance of evidence-based clinical efficacy assessments in contributing to better care decisions, Donna Sweet, MD, MACP today told the Subcommittee on Health of the House Energy and Commerce Committee. Dr. Sweet testified at a hearing, Breast Cancer Screening Recommendations, on behalf of the American College of Physicians (ACP).
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it has reached agreement with the U.S. Food and Drug Administration for two special protocol assessments for the Company's pivotal Phase 3 program with NAV5001 as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor.
Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and at Ghent University in Ghent, Belgium, have identified a new role for certain lung cells in the immune response to airborne allergens.
› Verified 8 days ago
Punxsutawney Area Hospital Acute Care Hospital Location: 81 Hillcrest Drive, Punxsutawney, Pennsylvania 15767 Phone: (814) 938-1800 |